THE INTRAPLEURAL ADMINISTRATION OF RECOMBINANT INTERLEUKIN-2 (RIL-2) TO PATIENTS WITH MALIGNANT PLEURAL EFFUSION - CLINICAL-TRIALS

被引：8

作者：

SUZUKI, H

ABO, S

KITAMURA, M

HASHIMOTO, M

IZUMI, K

机构：

[1] The Second Department of Surgery, Akita University School of Medicine, Akita, 010

来源：

SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1993年 / 23卷 / 12期

关键词：

RIL-2; MALIGNANT PLEURAL EFFUSION; INTRAPLEURAL ADMINISTRATION; LYMPHOKINE-ACTIVATED KILLER ACTIVITY;

D O I：

10.1007/BF00309093

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Recombinant IL-2 (rIL-2) was administered intrapleurally according to an original protocol to 11 patients with malignant pleural effusion, 7 of whom suffered from breast cancer and 4 from esophageal cancer. The pleural effusions either disappeared or decreased roentgenographically, and malignant cells disappeared from all 13 pleural cavities in the 11 patients, confirming the validity of this therapy to be 100%. The mean survival time from the initial administration of rIL-2 was 15.9 months. We ensured that the concentration of IL-2 in the effusion was maintained at a high level for a sufficient period of time, and that the lymphokine-activated killer (LAK) activity of lymphocytes in the effusion was augmented. Fever, eosinophilia, and a transient increase in the pleural effusion were the main side effects, but the symptoms were temporary and not serious. The results of this study therefore suggest the efficacy of intrapleural rIL-2 for patients with malignant pleural effusion.

引用

页码：1053 / 1059

页数：7

共 22 条

[1]

Morgan D.A., Ruscetti F.W., Gallo R., Selective in vitro growth of T lymphocytes from normal human bone marrows, Science, 193, pp. 1007-1008, (1976)

[2]

Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., Hamuro J., Structure and expression of a cloned cDNA for human interleukin-2, Nature, 302, pp. 305-310, (1983)

[3]

Grimm E.A., Mazumler A., Zhang H.Z., Rosenberg S.A., Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistent fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes, J Exp Med, 155, pp. 1823-1841, (1982)

[4]

Rosenberg S.A., Lotze M.T., Muul L.M., Susan L., Chang A.E., Ettinghausen S.E., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med, 313, pp. 1485-1492, (1985)

[5]

Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., Linehan W.M., Robertson C.N., Lee R.E., Rubin J.T., Seipp C.A., Simpson C.G., White D.E., A progress report on treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N Engl J Med, 316, pp. 889-897, (1987)

[6]

Lotze M.T., Matory Y.L., Ettinghausen S.E., Rayer A.A., Sharrow S.O., Seipp C.A., Custer M.C., Rosenberg S.A., In vivo administration of purified human interleukin 2: II. Half life, immunologic effect, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2, J Immunol, 135, pp. 2865-2875, (1985)

[7]

Lotze M.T., Matory Y.L., Rayner A.A., Ettinghausen S.E., Vetto J.T., Seipp C.A., Rosenberg S.A., Clinical effects and toxicity of interleukin-2 in patients with cancer, Cancer, 58, pp. 2764-2772, (1986)

[8]

Hinuma S., Naruo K., Shiho O., Tsukamoto K., Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2, Immunol, 59, pp. 251-259, (1986)

[9]

Kaplan E.L., Meier P., Nonparametric estimation from incomplete observations, Journal of the American Statistical Association, 53, pp. 457-481, (1958)

[10]

Lee R.E., Lotze M.T., Skibber J.M., Tucker E., Bonow R.O., Ognibene F.P., Carrasquillo J.A., Shelhamer J.H., Parrillo J.E., Rosenberg S.A., Cardiorespiratory effects of immunotherapy with interleukin-2, J Clin Oncol, 7, pp. 7-20, (1989)

← 1 2 3 →